https://www.fiercepharma.com/pharma/astrazeneca-lynparza-combo-fda-advisory-committee-prostate-cancer-vote
0
0
With negative FDA panel vote, AstraZeneca may look at narrow Lynparza nod in prostate cancer - FiercePharma
4/28/23 at 7:51pm
Organization
FiercePharma
Author
FiercePharma
Details
16 words
Summarize
Create an account or login to join the discussion